Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 23;10(58):35185-35197.
doi: 10.1039/d0ra04987e. eCollection 2020 Sep 21.

P-stereocontrolled synthesis of oligo(nucleoside N3'→O5' phosphoramidothioate)s - opportunities and limitations

Affiliations

P-stereocontrolled synthesis of oligo(nucleoside N3'→O5' phosphoramidothioate)s - opportunities and limitations

Ewa Radzikowska et al. RSC Adv. .

Abstract

3'-N-(2-Thio-1,3,2-oxathiaphospholane) derivatives of 5'-O-DMT-3'-amino-2',3'-dideoxy-ribonucleosides (NOTP-N), that bear a 4,4-unsubstituted, 4,4-dimethyl, or 4,4-pentamethylene substituted oxathiaphospholane ring, were synthesized. Within these three series, NOTP-N differed by canonical nucleobases (i.e., AdeBz, CytBz, GuaiBu, or Thy). The monomers were chromatographically separated into P-diastereomers, which were further used to prepare NNPSN' dinucleotides (3), as well as short P-stereodefined oligo(deoxyribonucleoside N3'→O5' phosphoramidothioate)s (NPS-) and chimeric NPS/PO- and NPS/PS-oligomers. The condensation reaction for NOTP-N monomers was found to be 5-6 times slower than the analogous OTP derivatives. When the 5'-end nucleoside of a growing oligomer adopts a C3'-endo conformation, a conformational 'clash' with the incoming NOTP-N monomer takes place, which is a main factor decreasing the repetitive yield of chain elongation. Although both isomers of NNPSN' were digested by the HINT1 phosphoramidase enzyme, the isomers hydrolyzed at a faster rate were tentatively assigned the R P absolute configuration. This assignment is supported by X-ray analysis of the protected dinucleotide DMTdGiBu NPSMeTOAc, which is P-stereoequivalent to the hydrolyzed faster P-diastereomer of dGNPST.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Chart 1
Chart 1. B1,B2 = Ade, Cyt, Gua or Thy. The asterisks indicate the P-stereogenic centers.
Scheme 1
Scheme 1. A mechanism of the DBU-promoted condensation step in Otp synthesis of NPSN′ or NNPSN′ with the use of a mixture of P-epimers of OTP-N (Z = O) or NOTP-N monomers (Z = NH), respectively. 4, R = H; 5, R = Me; 6, R,R = −(CH2)5–. B′ = AdeBz, CytBz, GuaiBu, or Thy. The codes 6Gf and 6Gs indicate fast- and slow-eluting P-diastereomers of Pm-NOTP-dG (vide infra).
Chart 2
Chart 2. (D) (Rc)-2-(1-(α-Naphthyl)ethyl)amino)-2-thio-1,3,2-oxathiaphospholane, (E) a 2-thio-1,3,2-oxathiaphospholane derivative of l-tryptophan methyl ester; NOTP-Trp.
Scheme 2
Scheme 2. Effects of silica gel separation of P-diastereomers of 2-thio-1,3,2-oxathiaphospholane monomers 4–6. The descriptors pro-RP and pro-SP indicate the absolute configuration of P-atom in the subsequently formed internucleotide phosphoramidothioate linkages. The structure F is given only for comparison with G.
Chart 3
Chart 3. Orientation of the sulfur, phosphoryl oxygen and thymidine O5′ atoms around the phosphorus atoms: Panel A, in phosphorothioate SP-1, ref. 23; Panel B, 2D NMR ROESY based assignment (here challenged by X-ray analysis of 10f, Scheme 1) in the S-methylated SP-3Mf, ref. 22 (the phosphoramidothioate diester precursor was obtained from fast-eluting 5Tf). The Arabic numerals 1–4 indicate the priority of substituents around the phosphorus atoms according to the Cahn–Ingold–Prelog rules. Note: to establish the priority of substituents, the formal double bond between the phosphoryl oxygen atom and the phosphorus atom (PO) should be considered a single one.
Fig. 1
Fig. 1. Crystal structure of DMTdGiBuNPSMeTOAc10f showing partial structure and spatial orientation of substituents around the phosphorus stereogenic center (marked P1). Compound 10 was obtained from the monomer 6Gf (fast-eluting 5′-O-DMT-3′-amino-2′,3′-dideoxy-N6-iBu-guanosine-3′-N-(2-thio-4,4-pentamethylene-1,3,2-oxathiaphospholane). The oxygen atom marked O5′A belongs to the thymidine residue.
Scheme 3
Scheme 3. The HINT1 catalyzed hydrolysis of adenosine-5′-O-((l-tryptophan amide-Nα-yl)-phosphoramidothioate) (AMPS-Trp-NH2), followed by desulfuration of the AMPS intermediate leading to the formation of adenosine-5′-O-phosphate.
Fig. 2
Fig. 2. Rates of hydrolysis of NPS-dinucleotides 11–17 (data from Table 2). The descriptions fast and slow refer to the relative chromatographic mobility of NOTP-N precursors. For better visualization the heights of bars depicting the rates of hydrolysis of 16 and 17 have been scaled up by a factor of 10.
Fig. 3
Fig. 3. Coupling yields in the consecutive condensation steps, assessed by DMT+ assay at 504 nm. Absorptions of the DMT+ cation released from the nucleosides attached to the support (blue bars) are taken as 100%.
Fig. 4
Fig. 4. Visualization of the lowest energy conformers of 6G (RPPm-NOTP-dG and SPPm-NOTP-dG). The data were obtained using the Gaussian 16 package. Heteroatom labeling: P-green, O-red, S-yellow, N-navy blue.
Fig. 5
Fig. 5. Visualization of the lowest energy conformer of RP-5T (the C2′-endo atom is marked with an arrow). The data were obtained using the Gaussian 16 package. Heteroatom labeling: P-green, O-red, S-yellow, N-navy blue.
Fig. 6
Fig. 6. Predicted by molecular modeling the lowest energy conformations of: SPPm-OTP-dA, an upper panel; RP-6A, a middle panel; RP-5T, a bottom panel. All three compounds are P-stereochemically equivalent (vide supra).
Fig. 7
Fig. 7. Analysis of 21f obtained from 5Tf. (Left) An RP HPLC profile (DMT-OFF); (right): an electropherogram (20% PAGE).

Similar articles

Cited by

References

    1. Zamecnik P. C. Stephenson M. L. Proc. Natl. Acad. Sci. U. S. A. 1978;75:280. doi: 10.1073/pnas.75.1.280. - DOI - PMC - PubMed
    2. Kurreck J. Eur. J. Biochem. 2003;270:1628. doi: 10.1073/pnas.75.1.280. - DOI - PubMed
    3. Kole R. Krainer A. R. Altman S. Nat. Rev. Drug Discovery. 2012,;11:12. doi: 10.1073/pnas.75.1.280. - DOI - PMC - PubMed
    1. Eckstein F. Antisense Nucleic Acid Drug Dev. 2000;10:117. doi: 10.1089/oli.1.2000.10.117. - DOI - PubMed
    2. Guga P. Koziołkiewicz M. Chem. Biodiversity. 2011;8:1642. doi: 10.1002/cbdv.201100130. - DOI - PubMed
    3. Eckstein F. Nucleic Acid Ther. 2014;24:374. doi: 10.1089/nat.2014.0506. - DOI - PubMed
    4. Volk D. E. Lokesh G. L. R. Biomedicines. 2017;5:41. doi: 10.3390/biomedicines5030041. - DOI - PMC - PubMed
    5. Shen X. Corey D. R. Nucleic Acids Res. 2018;46:1584. doi: 10.1093/nar/gkx1239. - DOI - PMC - PubMed
    1. Wilk A. Stec W. J. Nucleic Acids Res. 1995;23:530. doi: 10.1093/nar/23.3.530. - DOI - PMC - PubMed
    1. Stec W. J. Karwowski B. Boczkowska M. Guga P. Koziołkiewicz M. Sochacki M. Wieczorek M. Błaszczyk J. J. Am. Chem. Soc. 1998;120:7156. doi: 10.1021/ja973801j. - DOI
    2. Guga P. and Stec W. J., in Current Protocols in Nucleic Acid Chemistry, ed. S. L. Beaucage, D. E. Bergstrom, G. D. Glick and R. A. Jones, John Wiley and Sons, Hoboken, N.J., 2003, p. 4.17.1 - PubMed
    1. Wilk A. Grajkowski A. Phillips L. R. Beaucage S. L. J. Am. Chem. Soc. 2000;122:2149. doi: 10.1021/ja991773u. - DOI
    2. Oka N. Yamamoto M. Sato T. Wada T. J. Am. Chem. Soc. 2008;130:16031. doi: 10.1021/ja991773u. - DOI - PubMed
    3. Knouse K. W. deGruyter J. N. Schmidt M. A. Zheng B. Vantourout J. C. Kingston C. Mercer S. E. Mcdonald I. M. Olson R. E. Zhu Y. Hang C. Zhu J. Yuan C. Wang Q. Park P. Eastgate M. D. Baran P. S. Science. 2018;361:1234. doi: 10.1021/ja991773u. - DOI - PMC - PubMed
    4. Iwamoto N. Butler D. C. D. Svrzikapa N. Mohapatra S. Zlatev I. Sah D. W. Y. Meena Standley S. M. Lu G. Apponi L. H. Frank-Kamenetsky M. Zhang J. J. Vargeese C. Verdine G. L. Nat. Biotechnol. 2017;35:845. doi: 10.1021/ja991773u. - DOI - PubMed